EGFR and KRAS mutations were demonstrated to have close relationship to the -responses of erlotinib and gefitinib in non-small cell lung cancer (NSCLC). Objectives: applying PCR RFLP technique to detect exon 18-21 EGFR mutations and codon 12-13 KRAS muatations from NSCLC tissues. Patients and methods: 40 paraffin-embedded NSCLC tissues were selected. DNA were extracted from tissues. Exons of EGFR and KRAS gen were amplified. PCR products were digested by specific restrictive enzymes and performed by agarose electrosporesis. Mutations were confirmed by direct sequencing. Results: 4 types of exon 18-21 EGFR mutations in 19/40 samples (47,5 percent) and 2 types of codon 12-13 KRAS mutations in 5/40 samples (12,5 percent) were detected by PCR RFLP. Although has higher sensitivity than direct sequencing, PCR RFLP can't detect not-published EGFR mutations and can't determined precisely KRAS mutations. Conclusions: PCR RFLP procedures for EGFR and KRAS muatations in NSCLC were optimized.
- Đăng nhập để gửi ý kiến